Product Overview
REGRANEX Gel is the first and only FDA-approved recombinant platelet-derived growth factor (PDGF) therapy for use on diabetic neuropathic ulcers.
REGRANEX (becaplermin) Gel, 0.01% contains becaplermin, a human platelet-derived growth factor that is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. REGRANEX Gel is indicated as an adjunct to, and not a substitute for, good ulcer care practices.
Endogenous platelet-derived growth factor (PDGF) is the catalyst that initiates healing by attracting repair cells to revitalize wounds. PDGF works to stimulate fibroblast proliferation to increase granulation tissue, increase the rate of reepithelialization and revascularization and promote collagen production.
(http://www.smith-nephew.com/)
